Patents by Inventor Kamon Shirakawa

Kamon Shirakawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10676532
    Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: June 9, 2020
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon Shirakawa
  • Publication number: 20180237537
    Abstract: The present invention provides anti-presepsin polyclonal antibodies specifically binding to a peptide comprising an amino acid sequence of SEQ ID NO: 1. As a result, anti-presepsin polyclonal antibodies which have less variation in measured values between lot-to-lot differences of antibodies compared to S68 antibodies and thus suitable anti-presepsin polyclonal antibodies for presepsin measurement are provided.
    Type: Application
    Filed: August 25, 2015
    Publication date: August 23, 2018
    Applicant: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon SHIRAKAWA
  • Patent number: 10054585
    Abstract: Methods for detecting respiratory infection associated with bacterial infection are described, in which the values of soluble CD14 antigen subtype (“sCD14-ST”) in the urine sample can be used to select a patient with a respiratory infection to whom antibiotic can be beneficially administered. The methods of this disclosure can also be used to determine the timing for ending administration of the antibiotic to the patient with respiratory infection associated with bacterial infection.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: August 21, 2018
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon Shirakawa
  • Publication number: 20180201688
    Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.
    Type: Application
    Filed: March 8, 2018
    Publication date: July 19, 2018
    Applicant: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon SHIRAKAWA
  • Patent number: 10024869
    Abstract: According to the methods for detecting respiratory infection associated with bacterial infection of the present invention, the values of soluble CD14 antigen subtype (“sCD14-ST”) in the blood sample can be used to select a patient with a respiratory infection to whom the antibiotic can be administered. The methods of this disclosure can also be used to determine the timing for ending administration of the antibiotic to the patient with respiratory infection.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: July 17, 2018
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon Shirakawa
  • Patent number: 9951142
    Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: April 24, 2018
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon Shirakawa
  • Publication number: 20160169889
    Abstract: Provided are a method for detecting respiratory infection associated with bacterial infection, a method for selecting patients with respiratory infection to receive an antibiotic, and a method for determining the timing for ending administration of an antibiotic to a patient with respiratory infection receiving the antibiotic, wherein said methods are characterized in that they are able to appropriately select patients with respiratory infection to whom the antibiotic is to be administered, to adjust the administration period of the antibiotic, and to treat respiratory infection associated with bacterial infection, and in that a measured value of sCD14-ST in urine is used as an indication.
    Type: Application
    Filed: February 19, 2016
    Publication date: June 16, 2016
    Applicant: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon Shirakawa
  • Publication number: 20160161506
    Abstract: Provided are a method for detecting respiratory infection associated with bacterial infection, a method for selecting patients with respiratory infection to receive an antibiotic, and a method for determining the timing for ending administration of an antibiotic to a patient with respiratory infection receiving the antibiotic, wherein said methods are characterized in that they are able to appropriately select patients with respiratory infection to whom the antibiotic is to be administered, to adjust the administration period of the antibiotic, and to treat respiratory infection associated with bacterial infection, and in which a measured value of sCD14-ST in blood is used as an indication.
    Type: Application
    Filed: February 11, 2016
    Publication date: June 9, 2016
    Inventor: Kamon Shirakawa
  • Patent number: 9297802
    Abstract: According to the method for detecting respiratory infection associated with bacterial infection of the present invention, the measured value of soluble CD14 antigen subtype (“sCD14-ST) in the urine sample can be used to select a patient with a respiratory infection to whom the antibiotic can be administered.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: March 29, 2016
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon Shirakawa
  • Patent number: 9291631
    Abstract: According to the method for detecting respiratory infection associated with bacterial infection of the present invention, the measured value of soluble CD14 antigen subtype (“sCD14-ST) in the blood sample can be used to select a patient with a respiratory infection to whom the antibiotic can be administered.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: March 22, 2016
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon Shirakawa
  • Publication number: 20150239982
    Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.
    Type: Application
    Filed: February 25, 2015
    Publication date: August 27, 2015
    Applicant: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon SHIRAKAWA
  • Publication number: 20140213507
    Abstract: Provided are a method for detecting respiratory infection associated with bacterial infection, a method for selecting patients with respiratory infection to receive an antibiotic, and a method for determining the timing for ending administration of an antibiotic to a patient with respiratory infection receiving the antibiotic, wherein said methods are characterized in that they are able to appropriately select patients with respiratory infection to whom the antibiotic is to be administered, to adjust the administration period of the antibiotic, and to treat respiratory infection associated with bacterial infection, and in which a measured value of sCD14-ST in blood is used as an indication.
    Type: Application
    Filed: May 18, 2012
    Publication date: July 31, 2014
    Inventor: Kamon Shirakawa
  • Publication number: 20140171359
    Abstract: Provided are a method for detecting respiratory infection associated with bacterial infection, a method for selecting patients with respiratory infection to receive an antibiotic, and a method for determining the timing for ending administration of an antibiotic to a patient with respiratory infection receiving the antibiotic, wherein said methods are characterized in that they are able to appropriately select patients with respiratory infection to whom the antibiotic is to be administered, to adjust the administration period of the antibiotic, and to treat respiratory infection associated with bacterial infection, and in that a measured value of sCD14-ST in urine is used as an indication.
    Type: Application
    Filed: May 18, 2012
    Publication date: June 19, 2014
    Inventor: Kamon Shirakawa
  • Publication number: 20140044723
    Abstract: The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.
    Type: Application
    Filed: July 24, 2013
    Publication date: February 13, 2014
    Inventors: Hiroshi Takayama, Kamon Shirakawa, Shoji Furusako, Yoshitaka Hosaka, Tomokazu Matsusue, Katsuki Naitoh, Yumi Hotta, Tetsushi Kawahara, Motoyasu Honda
  • Publication number: 20130288276
    Abstract: Disclosed is a prediction method for the prognosis of sepsis comprising measuring an sCD14-ST level in a sample. sCD14-ST, to be measured in the present invention, is a marker superior to procalcitonin, known as a marker to predict the prognosis in sepsis patients.
    Type: Application
    Filed: January 10, 2012
    Publication date: October 31, 2013
    Applicants: MOCHIDA PHARMACEUTICAL CO., LTD., Mitsubishi Chemical Medience Corporation
    Inventors: Takeshi Matsuya, Yoshikazu Okamura, Ralf Thomae, Eberhard Spanuth, Boris Ivandic, Kamon Shirakawa, Shigeatsu Endo
  • Publication number: 20130280252
    Abstract: The present invention is a method for selecting a patient to be given a drug for treating septicemia the mode of action of which is to interrupt toll-like receptor 4-derived intracellular signaling. The provided method comprises a step for measuring sCD14-ST in a blood sample from a subject, a step for comparing the measured value with a cut-off value, and a step for selecting a patient as the patient to be given the drug for the treatment of septicemia when the measured value of the sample of that patient is positive in comparison to the cut-off value. The present invention makes it possible to provide a drug to be given to a specific patient to treat septicemia, the mode of action of which is to interrupt toll-like receptor 4-derived intracellular signaling, and to appropriately select the patient to be given the drug and the administration timing or dose.
    Type: Application
    Filed: January 5, 2012
    Publication date: October 24, 2013
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Mariko Imai, Kamon Shirakawa
  • Patent number: 8524870
    Abstract: The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: September 3, 2013
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Hiroshi Takayama, Kamon Shirakawa, Shoji Furusako, Yoshitaka Hosaka, Tomokazu Matsusue, Katsuki Naitoh, Yumi Hotta, Tetsushi Kawahara, Motoyasu Honda
  • Patent number: 8389692
    Abstract: The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: March 5, 2013
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Hiroshi Takayama, Kamon Shirakawa, Shoji Furusako, Yoshitaka Hosaka, Tomokazu Matsusue, Katsuki Naitoh, Yumi Hotta, Tetsushi Kawahara, Motoyasu Honda
  • Patent number: 8124722
    Abstract: There are provided a soluble CD14 antigen which is a novel in vivo protein useful as a marker for diagnosing sepsis and has the following characteristic features 1) to 3): 1) a molecular weight of 13±2 kDa when measured by SDS-PAGE under non-reducing conditions; 2) an amino acid sequence in which the amino acid sequence of SEQ ID NO:1 is present on its N terminal; and 3) ability to specifically bind to an antibody prepared by using a peptide comprising 16 amino acid residues described in SEQ ID NO:2 for the antigen; and a recombinant soluble CD14 fragment.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: February 28, 2012
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Shoji Furusako, Kamon Shirakawa, Jiro Hirose
  • Publication number: 20110217318
    Abstract: The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.
    Type: Application
    Filed: April 27, 2011
    Publication date: September 8, 2011
    Inventors: HIROSHI TAKAYAMA, KAMON SHIRAKAWA, SHOJI FURUSAKO, YOSHITAKA HOSAKA, TOMOKAZU MATSUSUE, KATSUKI NAITOH, YUMI HOTTA, TETSUSHI KAWAHARA, MOTOYASU HONDA